Breaking News, Collaborations & Alliances

U.S. Invests $472mn More in Moderna

Expansion of BARDA deal supports mRNA-1273 clinical development plan including 30,000 participant Phase 3 COVE study conducted in collaboration with NIH.

By: Contract Pharma

Contract Pharma Staff

Moderna has unveiled a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the company’s mRNA vaccine candidate (mRNA-1273) against COVID-19.   An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated numb...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters